Indra A. Van Assche
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Indra A. Van Assche has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Frédéric Amant
Department of oncology, KU Leuven, Leuven, Belgium
5 shared publications Monica Fumagalli
University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
3 shared publicationsElisabeth M. van Dijk-Lokkart
Department of Child & Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, the Netherlands
2 shared publicationsElyce Cardonick
Cooper University Health Care, Department of Obstetrics and Gynecology, Camden, NJ, USA
2 shared publications- Evangeline A Huis In 'T Veld
Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands; Cancer Center Amsterdam, research program, Amsterdam, The Netherlands
2 shared publications - Jurgen Lemiere
Department of Oncology, Unit of Pediatric Oncology, KU Leuven, Belgium
2 shared publications
Latest Publications
- 15 July 2025
- Published by Elsevier in Annals of Oncology
- Vol. 36 (10) , 1235-1237
Reply to the Letter to the Editor by Szarpak et al.
- 15 July 2025
- Published by Elsevier in Annals of Oncology
- Vol. 36 (10) , 1235-1237
Reply to the Letter to the Editor by Szarpak et al.
- 13 June 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (9) , 101975
ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy
- 13 June 2025
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 35 (9) , 101975
ESGO/INCIP Guidelines for the management of patients with gynecological cancers during pregnancy
- Open Access
- 10 November 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 78, 102922
Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study
- 10 November 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 78, 102922
Open AccessChild outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study
- Open Access
- 28 February 2024
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 103 (4) , 757-760
Long‐term outcomes of children after prenatal exposure to maternal cancer and its treatment
The incidence of antenatal cancer is increasing, prompting a medical‐ethical evaluation. The International Network on Cancer, Infertility, and Pregnancy (INCIP) was established to study cancer treatment safety during pregnancy and its impact on maternal and child health. Pivotal research has led to a paradigm shift in clinical management, demonstrating the feasibility and safety of most antenatal oncological treatments. Short‐term outcomes reveal normal growth and cardiac function in the exposed offspring, but caution is advised against first‐trimester chemotherapy. Psychological impact studies highlight the elevated levels of distress in pregnant cancer patients, underscoring the need for personalized information and ongoing psychological support. Long‐term follow‐up studies address gaps in postnatal impacts, while research into specific chemotherapeutic agents continues. Despite generally reassuring outcomes, continued monitoring is crucial, especially in families, such as those where the child was born premature after cancer (treatment) during pregnancy or where mothers are frequently absent due to continued illness or have died from. The ongoing INCIP child follow‐up initiative aims to further elucidate knowledge gaps, emphasizing the importance of large‐scale studies and personalized patient care.
- 28 February 2024
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 103 (4) , 757-760
Open AccessLong‐term outcomes of children after prenatal exposure to maternal cancer and its treatment
The incidence of antenatal cancer is increasing, prompting a medical‐ethical evaluation. The International Network on Cancer, Infertility, and Pregnancy (INCIP) was established to study cancer treatment safety during pregnancy and its impact on maternal and child health. Pivotal research has led to a paradigm shift in clinical management, demonstrating the feasibility and safety of most antenatal oncological treatments. Short‐term outcomes reveal normal growth and cardiac function in the exposed offspring, but caution is advised against first‐trimester chemotherapy. Psychological impact studies highlight the elevated levels of distress in pregnant cancer patients, underscoring the need for personalized information and ongoing psychological support. Long‐term follow‐up studies address gaps in postnatal impacts, while research into specific chemotherapeutic agents continues. Despite generally reassuring outcomes, continued monitoring is crucial, especially in families, such as those where the child was born premature after cancer (treatment) during pregnancy or where mothers are frequently absent due to continued illness or have died from. The ongoing INCIP child follow‐up initiative aims to further elucidate knowledge gaps, emphasizing the importance of large‐scale studies and personalized patient care.
- Open Access
- 10 March 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (8) , 1527-1532
Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. This multicenter cohort study reports on the long-term effects of prenatal exposure to maternal cancer and its treatment on cognitive and behavioral outcomes in 9-year-old children. In total, 151 children (mean age, 9.3 years; range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral questionnaires. During pregnancy, 109 children (72.2%) were exposed to chemotherapy (only or in combination with other treatment modalities), 18 (11.9%) to surgery only, 16 (10.6%) to radiotherapy, one to trastuzumab, and 16 (10.6%) were not exposed to oncologic treatment. Mean cognitive and behavioral outcomes were within normal ranges. Gestational age at birth showed a positive association with Full Scale Intelligence Quotient (FSIQ), with the average FSIQ score increasing by 1.6 points for each week increase in gestational age (95% CI, 0.7 to 2.5; P < .001). No difference in FSIQ was found between treatment types (F[4,140] = 0.45, P = .776). In children prenatally exposed to chemotherapy, no associations were found between FSIQ and chemotherapeutic agent, exposure level, or timing during pregnancy. These results indicate a reassuring follow-up during the critical maturational period of late childhood, when complex functions develop and rely on the integrity of early brain development. However, associations were observed with preterm birth, maternal death, and maternal education.
- 10 March 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (8) , 1527-1532
Open AccessCognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. This multicenter cohort study reports on the long-term effects of prenatal exposure to maternal cancer and its treatment on cognitive and behavioral outcomes in 9-year-old children. In total, 151 children (mean age, 9.3 years; range, 7.8-10.6 years) were assessed using a neurocognitive test battery and parent-report behavioral questionnaires. During pregnancy, 109 children (72.2%) were exposed to chemotherapy (only or in combination with other treatment modalities), 18 (11.9%) to surgery only, 16 (10.6%) to radiotherapy, one to trastuzumab, and 16 (10.6%) were not exposed to oncologic treatment. Mean cognitive and behavioral outcomes were within normal ranges. Gestational age at birth showed a positive association with Full Scale Intelligence Quotient (FSIQ), with the average FSIQ score increasing by 1.6 points for each week increase in gestational age (95% CI, 0.7 to 2.5; P < .001). No difference in FSIQ was found between treatment types (F[4,140] = 0.45, P = .776). In children prenatally exposed to chemotherapy, no associations were found between FSIQ and chemotherapeutic agent, exposure level, or timing during pregnancy. These results indicate a reassuring follow-up during the critical maturational period of late childhood, when complex functions develop and rely on the integrity of early brain development. However, associations were observed with preterm birth, maternal death, and maternal education.
- Open Access
- 19 March 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 92 (7) , 543-551
Associations Between Statin Use and Negative Affective Bias During COVID-19: An Observational, Longitudinal UK Study Investigating Depression Vulnerability
- 19 March 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 92 (7) , 543-551
Open AccessAssociations Between Statin Use and Negative Affective Bias During COVID-19: An Observational, Longitudinal UK Study Investigating Depression Vulnerability